A study by the Ministry of Health and the Pharmaceutical Company found that the vaccine reduced asymptomatic infection by 90.4% and showed an anti-coronary infection of 94.1%.
The Ministry of Health and Pfizer jointly publish their findings regarding the effectiveness of the vaccine for corona.
According to the study, the vaccine demonstrated high efficacy and led to a decrease in coronary heart disease, morbidity, hospitalization, and for the first time provides evidence of reduced mortality.
According to the study, the effectiveness of the vaccine against corona infection stands at 94.1%, a week after the second dose.
It was also found that the vaccine reduced asymptomatic infection by 90.4% and symptomatic infection by 96.3%.
In addition, the vaccine was found to reduce the risk of hospitalization by 96% and 96.2% for hospitalization in a critical condition.
The vaccine reduced the risk of mortality by 93.3%.
The figure rose to 96% two weeks after the second vaccine.
"Infection is avoided"
The study analyzed current data up to March 6 and includes immunization data of 51.5% of the population aged 16 and over in Israel who received two doses of vaccine.
"Two vaccine doses have shown high efficacy in preventing corona virus infection, morbidity, hospitalizations, hospitalizations in critical condition and mortality," the researchers noted.
Meanwhile, Pfizer, in cooperation with the German company Biontech, announced yesterday that it has begun the first comprehensive trial of its type of corona vaccine on children under 12, with the company expecting to receive approval to vaccinate children in this age range by early 2022.
According to the company's announcement, the first subjects in the trial received the vaccine shot yesterday.
The experiment in children also includes six-month-old infants.
The child vaccination program will include, in the first phase, 144 trials of various ages and will later be expanded to 4,500 trials.
The company intends to test side effects and antibody levels produced by the vaccine, while giving the vaccine two injections three weeks apart.
A company spokeswoman said they expect preliminary results during the second half of 2021. In addition, Pfizer has conducted a large trial of the corona vaccine among boys aged 15-12 and is expecting the results of the trial as early as the coming weeks.